Jiangxi Rimag Group Co Ltd
Jiangxi Rimag Group Co Ltd operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the production and sale of pharmaceutical products.
Business. Jiangxi Rimag Group Co Ltd (2522.HK) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Headquartered in China, the company is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Jiangxi Rimag Group Co Ltd (2522.HK) is a healthcare services and equipment company primarily engaged in pharmaceutical activities. The firm operates within the Healthcare Facilities & Services industry, generating revenue through service-based models. Headquartered in China, the company is listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.
Jiangxi Rimag Group Co Ltd has a market capitalization of 3.07 billion CNY, with a market price of 7.77 CNY per share. The company has no dilution risk, as the number of basic and diluted shares outstanding is identical at 395,325,332 shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
Profitability metrics are not available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. Analysts have assigned a mean recommendation of 2.00, indicating a "Buy" rating, with one analyst recommending a "Buy" and none recommending a "Strong Buy" or "Strong Sell". The most recent actual EPS was 0.01 CNY, significantly below the mean EPS estimate of 0.20 CNY, suggesting a potential earnings shortfall.
Segment and geographic exposure details are not disclosed in the available data. The company's revenue concentration and geographic diversification remain opaque, limiting the ability to assess exposure to regional or product-specific risks.
The company's growth trajectory is uncertain, as no outlook data is provided for the current or next fiscal year. The absence of revenue history and forward-looking guidance makes it difficult to assess growth potential or strategic direction.
Risk factors include the inability to assess liquidity risk and the potential for earnings to fall short of analyst estimates. No dilution sources are identified, and no adjustments have been applied to the valuation metrics.
Recent events, including filings or transcripts, are not disclosed in the available data. The company's strategic developments and operational updates remain unreported, limiting visibility into near-term performance drivers.
- Jiangxi Rimag Group Co Ltd has a market capitalization of 3.07 billion CNY and no dilution risk.
- Analysts have assigned a "Buy" rating, but the most recent actual EPS was significantly below the mean estimate.
- Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language.
- The company's growth trajectory and segment exposure are not disclosed, limiting visibility into strategic direction.
- No recent events or filings are available, reducing transparency into operational developments.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue ¥873.1M, +14,8% YoY; Operating income +191,4% YoY.
- ▍Revenue ¥873.1M, +14,8% YoY
- ▍Operating income +191,4% YoY
- ▍Net income +108,2% YoY
- ▍Free cash flow +139,3% YoY
- ▍Net margin 0.4%
Revenue ¥760.6M, −18,1% YoY; Operating income −138,3% YoY.
- ▍Revenue ¥760.6M, −18,1% YoY
- ▍Operating income −138,3% YoY
- ▍Net income −203,4% YoY
- ▍Free cash flow −236,6% YoY
- ▍Net margin -6.0%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,20 |
| Revenue | —no estimate | —no estimate | 1,2B CNY |
| Operating income | —no estimate | —no estimate | 97,0M CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Jiangxi Rimag Group Co Ltd Market data — financials · 2026-05-26
- Jiangxi Rimag Group Co Ltd Market data — analyst estimates · 2026-05-26